The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FEATURE-Vulnerable children stay shut indoors in UK with no vaccine in sight

Mon, 01st Mar 2021 14:16

By Emma Batha

LONDON, March 1 (Thomson Reuters Foundation) - When
Britain's children return to school next week as the country
eases its third lockdown, six-year-old Daniel Meredith will not
be joining his friends but will remain shut indoors with no end
date in sight.

Daniel has complex medical conditions which could make a
COVID-19 infection fatal but there is no vaccine available for
children yet, leaving thousands of families with little option
but to continue shielding.

"We really do feel like the forgotten people," Daniel's
mother Sara Meredith, told the Thomson Reuters Foundation.

"Our lives are based around fear."

Britain, which has launched one of the world's fastest
vaccine roll-outs, has prioritised inoculations for clinically
vulnerable adults.

But with paediatric trials only just getting under way,
vulnerable children could have a long wait.

Disabilities charity Contact said 61,800 children in Britain
were at high risk of complications from COVID-19.

Some have been confined to their homes since before the
first lockdown began in March last year.

The pandemic has claimed more than 123,000 lives in Britain,
one of the world's worst hit countries.

But with over 20 million people now inoculated, restrictions
on socialising could begin to ease later this month.

Family reunions are not on the cards for Daniel, however.

Meredith, 40, said her son missed his grown-up sisters and
carers, who have been unable to visit them in Walsall, central
England, for a year.

"This has had a massive impact on him. He doesn't understand
about COVID. He sees it as nobody wants him," she said.

"Daniel loved school and was thriving. But I cannot see him
going back this year."

The lockdown has been particularly grueling for parents of
children requiring round-the-clock care like Daniel, whose fluid
levels need to be managed day and night.

Close to tears with exhaustion, Meredith said the family
used to get help from outside carers so she and her husband
could catch up on sleep during the day, but it was too risky to
have them in the house now.

PAEDIATRIC TRIALS

The University of Oxford said it was beginning trials of the
Oxford/AstraZeneca vaccine on children aged over six in a study
that will run until September 2022, but results could be
available this year.

Pfizer and BioNTech are already evaluating results from
trials of their vaccine on 12- to 15-year-olds. Studies in
over-fives are set for the coming months, and under-fives later
in the year.

The British government says most children are unlikely to
get ill from COVID-19, but in very exceptional circumstances
doctors may give a vaccine "off-licence" to high risk teenagers.

But parents who have tried to get their children immunised
said they had been sent around in circles.

London company director Yvonne Woodford has battled for
weeks to get a vaccine for her 13-year-old daughter Katherine,
who has Down's Syndrome and a respiratory condition requiring
her to use a ventilator at night.

She said Katherine's paediatrician had said she should have
the jab and their local doctor could provide it. But their
doctor, who initially also assumed he could give the vaccine,
later informed her he was not authorised to do so.

In a desperate bid to cut through the red tape, Woodford
took Katherine to her own vaccination appointment, armed with
the paediatrician's letter.

The centre told her they would be shut down if they
vaccinated Katherine.

Woodford is now pushing to get the issue raised in
parliament.

"All the doctors and consultants who know Katherine think
she should have it, but at the moment there's no way of it being
given to her," said the mother-of three.

The health department could not immediately say who, if
anyone, was authorised to give the vaccine "off-licence".
Britain's national health service and paediatric body also could
not shed light on this.

'VERY WORRYING'

Lockdown has not only impacted Katherine's schooling, but
also her health because she cannot go outdoors to exercise.

"We've shut down as much as we possibly can. We don't see
anyone," said Woodford, who has to keep an all-night vigil by
her daughter's bed several times a week after cutting back on
outside carers.

The situation has also impacted her two sons who have
remained largely cooped up indoors even when restrictions have
been eased.

"It's very worrying and absolutely exhausting," Woodford
said. "How long can you expect families to go on like this?"

Her frustrations are shared by Julie Nixon, a mother-of-six
who also fosters three boys with severe learning disabilities
and complex medical conditions at her home on the south coast.
Doctors say the oldest, James, would not survive COVID-19.

"Until he has his vaccine our life can't resume. We're
absolutely desperate for it," said Nixon, 53, who has been
honoured by the Queen for her work in caring for children with
disabilities.

She worries about the longterm impact on the physical health
of her foster sons, who have missed important medical
appointments and physiotherapy normally provided by their
school.

James has outgrown his spinal jacket, but Nixon cannot risk
taking him to hospital to get a new one fitted.

She has also kept her own school-age children off school for
fear they could bring the virus home.

"They have seen no friends, they have not been out and
about, and I worry about their mental health," Nixon said.

"Everyone in Britain is hanging on for the light at the end
of the tunnel now, but there's no light for us yet."
(Reporting by Emma Batha @emmabatha; Editing by Belinda
Goldsmith
Please credit the Thomson Reuters Foundation, the charitable arm
of Thomson Reuters, which covers the lives of people around the
world who struggle to live freely or fairly. Visit http://news.trust.org)

More News
Today 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.